Literature DB >> 23433232

A preliminary study suggests that nicotine and prefrontal dopamine affect cortico-striatal areas in smokers with performance feedback.

M R Lee1, C L Gallen, T J Ross, P Kurup, B J Salmeron, C A Hodgkinson, D Goldman, E A Stein, M A Enoch.   

Abstract

Nicotine and tonic dopamine (DA) levels [as inferred by catechol-O-methyl tranferase (COMT) Val158Met genotype] interact to affect prefrontal processing. Prefrontal cortical areas are involved in response to performance feedback, which is impaired in smokers. We investigated whether there is a nicotine × COMT genotype interaction in brain circuitry during performance feedback of a reward task. We scanned 23 healthy smokers (10 Val/Val homozygotes, 13 Met allele carriers) during two fMRI sessions while subjects were wearing a nicotine or placebo patch. A significant nicotine × COMT genotype interaction for BOLD signal during performance feedback in cortico-striatal areas was seen. Activation in these areas during the nicotine patch condition was greater in Val/Val homozygotes and reduced in Met allele carriers. During negative performance feedback, the change in activation in error detection areas such as anterior cingulate cortex (ACC)/superior frontal gyrus on nicotine compared to placebo was greater in Val/Val homozygotes compared to Met allele carriers. With transdermal nicotine administration, Val/Val homozygotes showed greater activation with performance feedback in the dorsal striatum, area associated with habitual responding. In response to negative feedback, Val/Val homozygotes had greater activation in error detection areas, including the ACC, suggesting increased sensitivity to loss with nicotine exposure. Although these results are preliminary due to small sample size, they suggest a possible neurobiological mechanism underlying the clinical observation that Val/Val homozygotes, presumably with elevated COMT activity compared to Met allele carriers and therefore reduced prefrontal DA levels, have poorer outcomes with nicotine replacement therapy. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23433232      PMCID: PMC3890256          DOI: 10.1111/gbb.12027

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  55 in total

Review 1.  D(1) receptors in prefrontal cells and circuits.

Authors:  P S Goldman-Rakic; E C Muly; G V Williams
Journal:  Brain Res Brain Res Rev       Date:  2000-03

2.  Smoking, reward responsiveness, and response inhibition: tests of an incentive motivational model.

Authors:  Jane Powell; Lynne Dawkins; Robert E Davis
Journal:  Biol Psychiatry       Date:  2002-01-15       Impact factor: 13.382

3.  Dorsal striatum responses to reward and punishment: effects of valence and magnitude manipulations.

Authors:  M R Delgado; H M Locke; V A Stenger; J A Fiez
Journal:  Cogn Affect Behav Neurosci       Date:  2003-03       Impact factor: 3.282

4.  Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers.

Authors:  C Martin-Soelch; J Missimer; K L Leenders; W Schultz
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

5.  The neural basis of human error processing: reinforcement learning, dopamine, and the error-related negativity.

Authors:  Clay B Holroyd; Michael G H Coles
Journal:  Psychol Rev       Date:  2002-10       Impact factor: 8.934

6.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.

Authors:  M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

7.  Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine.

Authors:  Venkata S Mattay; Terry E Goldberg; Francesco Fera; Ahmad R Hariri; Alessandro Tessitore; Michael F Egan; Bhaskar Kolachana; Joseph H Callicott; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

8.  Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study.

Authors:  P A Garris; R M Wightman
Journal:  J Neurosci       Date:  1994-01       Impact factor: 6.167

9.  Catechol-O-methyltransferase genotype and dopamine regulation in the human brain.

Authors:  Mayada Akil; Bhaskar S Kolachana; Debora A Rothmond; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

Review 10.  Antidepressants for smoking cessation.

Authors:  J R Hughes; L F Stead; T Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  4 in total

1.  Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs.

Authors:  Fabio Lugoboni; Frances Rudnick Levin; Maria Chiara Pieri; Matteo Manfredini; Lorenzo Zamboni; Lorenzo Somaini; Gilberto Gerra
Journal:  Psychiatry Res       Date:  2017-01-21       Impact factor: 3.222

2.  COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers.

Authors:  H Bowers; D Smith; S de la Salle; J Choueiry; D Impey; T Philippe; H Dort; A Millar; M Daigle; P R Albert; A Beaudoin; V Knott
Journal:  Genes Brain Behav       Date:  2015-07-15       Impact factor: 3.449

3.  White matter microstructure changes induced by motor skill learning utilizing a body machine interface.

Authors:  Xue Wang; Maura Casadio; Kenneth A Weber; Ferdinando A Mussa-Ivaldi; Todd B Parrish
Journal:  Neuroimage       Date:  2013-11-09       Impact factor: 6.556

4.  Nicotinergic Modulation of Attention-Related Neural Activity Differentiates Polymorphisms of DRD2 and CHRNA4 Receptor Genes.

Authors:  Thomas P K Breckel; Carsten Giessing; Anja Gieseler; Sarah Querbach; Martin Reuter; Christiane M Thiel
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.